论文部分内容阅读
目的:探讨培美曲塞二线治疗晚期非小细胞肺癌的临床疗效。方法:2008年1月—2012年1月56例接受含铂联合化疗方案一线治疗失败的ⅢB期和Ⅳ期非小细胞肺癌患者,接受单药培美曲塞(500 mg/m2,d 1)二线治疗,21 d为1个周期。化疗2个周期后评价近期疗效和不良反应。远期指标包括中位生存期和1年生存率。结果:本组56例患者完成2~6个周期培美曲塞治疗,共178个周期,均可评价疗效。其中,完全缓解0例,部分缓解9例(16.1%),疾病稳定19例(33.9%),疾病进展28例(50.0%),客观有效率为16.1%;中位生存期为8.9个月,1年生存率为30.35%。主要不良反应为骨髓抑制和胃肠反应,严重程度较轻,均可耐受,无治疗相关死亡。结论:培美曲塞二线治疗晚期非小细胞肺癌疗效确切,且不良反应可以耐受。
Objective: To investigate the clinical efficacy of pemetrexed second-line treatment of advanced non-small cell lung cancer. METHODS: From January 2008 to January 2012, 56 patients with stage ⅢB and Ⅳ non-small cell lung cancer who underwent first-line platinum-based chemotherapy regimens received pemetrexed monotherapy (500 mg / m2, d1) Second-line treatment, 21 d for a cycle. Evaluation of short-term efficacy and adverse reactions after 2 cycles of chemotherapy. Long-term measures include median survival and 1-year survival. Results: The 56 patients completed 2 to 6 cycles of pemetrexed treatment, a total of 178 cycles, can evaluate the efficacy. Among them, 0 cases were completely relieved, 9 cases (16.1%) were partly relieved, 19 cases (33.9%) were stable, 28 cases (50.0%) were disease progression, objective response rate was 16.1%, median survival was 8.9 months One-year survival rate was 30.35%. The main adverse reactions were myelosuppression and gastrointestinal reactions, which were less severe and tolerable without treatment-related death. Conclusion: Pemetrexed second-line treatment of advanced non-small cell lung cancer curative effect is exact, and adverse reactions can be tolerated.